Enzyme replacement therapy (ERT) is the primary treatment for Pompe disease. This therapy involves the intravenous infusion of recombinant human acid alpha glucosidase to supplement the deficient enzyme in patients. ERT has shown significant improvements in cardiac and muscular function, particularly in infantile-onset Pompe disease.
